SCHOTT Pharma, a drug containment and delivery solutions provider, has introduced a novel 10ml ready-to-use (RTU) cartridge designed to store sensitive biologics to treat a range of diseases and disorders.
The cartridges are compatible with on-body, self-injecting drug delivery devices — allowing patients to administer their medication from the comfort of their own home, rather than travelling to the hospital.
This allows for improved patient centricity of treatments, while also reducing costs on the healthcare system, according to SCHOTT.
YpsoDose and cartriQ: perfectly compatible
When combined with Ypsomed's on-body device YpsoDose, the system is the first to be prefilled and loaded, meaning less handling is required by the end-user. This can both enhance patient compliance and provide users with a simplified solution to therapeutic administration.
This large format solution is specifically designed to protect and administer highly sensitive biologics, which has the ability to transform the treatment landscape for a number of diseases, including metabolic disorders, cancer, genetic disorders, cardiovascular diseases and immunological diseases.
“With our large format RTU cartridges, we are actively supporting pharma companies, who are transitioning the drug administration from intravenous infusion to subcutaneous injection,” commented CEO of SCHOTT Pharma, Andreas Reisse. “We are thereby empowering patients to self-administer also large volume medications, which is a real game-changer for them. By facilitating the shift to homecare solutions, we are also helping to reduce the financial burden on the healthcare system.” The RTU cartridges known as cartriQ are available for human use (FHU) and are manufactured at the company’s site in St. Gallen, Switzerland.
As part of the SCHOTT iQ platform, cartriQ RTU cartridges come in a standardised nest and tub configuration, ensuring optimal container quality and enhancing fill-and-finish efficiency for pharma companies.
